Rachel Rutishauser is an Infectious Disease physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1001 Potrero Ave
Building 3, Room 603
San Francisco, CA 941103518
Telephone
415-206-8102Registry record last updated 28 Feb 2017.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20241 payment
- Gilead Sciences, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
44.3%Statin27.1%Atorvastatin Calcium100%Part D<11 patientsACE inhibitor17.1%Lisinopril100%Part D<11 patientsDermatology
18.6%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor18.6%Acyclovir100%Part D<11 patientsAnti-infectives
18.6%Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor18.6%Efavirenz-Emtric-Tenofov Disop100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 2018–2026 per NIH RePORTER. The latest:
- Optimizing engineered T cells with highly sensitive anti-HIV/Env HLA-independent T cell receptors (HITs)
University of California, San Francisco
FY2026$3,330,654R01AI198049 - Multi-omic understanding of the transformed host T-cell response to HIV following therapeutic vaccination
University of California at Davis
FY2026$1,575,640P01AI178375 - Modeling dynamic CD8+ T cell-virus interactions in post-treatment control of HIV
University of California, San Francisco
FY2026$874,531R01AI200744
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”